Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus;Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii ve Staphylococcus aureus klinik izolatlarιnda dιşa atιm pompa inhibitoörlerinin siprofloksasin MİK deǧerleri üzerine etkilerinin araştιrιlmasι

Mikrobiyoloji Bulteni

Volumn 42, Issue 4, 2008, Pages 553-561

  Çetinkaya, Ebru ^a   Çoban, Ahmet Yilmaz ^a   Durupinar, Belma ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; Ciprofloxacin; Efflux pump; Escherichia coli; Phenylalanyl arginyl naphtylamide; Pseudomonas aeruginosa; Reserpine; Resistance; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DIPEPTIDE; PHENYLALANINE ARGININE BETA NAPHTHYLAMIDE; PHENYLALANINE ARGININE BETA-NAPHTHYLAMIDE; RESERPINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; DRUG INTERACTION; ESCHERICHIA COLI; HUMAN; MICROBIOLOGICAL EXAMINATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER BAUMANNII; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DIPEPTIDES; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; RESERPINE; STAPHYLOCOCCUS AUREUS;

EID: 55949129718     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hasdemir U. The role of cell wall organization and active efflux pump systems in multidrug resistance of bacteria. Mikrobiyol Bul 2007; 41: 309-27.
2. Hasdemir U. Bakterilerin çoklu antimikrobiyal direncinde aktif pompa sistemleri. 7. Antimikrobik Kemoterapi Günleri: Klinik-Laboratuvar Uygulamalari ve Yenilikler. 2006, Istanbul. Kongre Kitabι, s: 125-35.
3. Ribera A, Ruiz J, Jiminez de Anta MT, Vila J. Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumonnii and Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2002; 49: 697-8.
4. Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 2005; 87: 1137-47.
5. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother 2000; 44: 2595-9.
6. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard, M7-A6. 2003, 6th ed. CLSI, Wayne, Pa.
7. Wright GD. Resisting resistance: new chemical strategies for battling superbugs. Chem Biol 2000; 7: 127-32.
8. Miller LA, Ratman K, Payne DJ. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001; 1: 451-8.
9. Hajduk PJ, Dinges J, Schkeryantz JM, et al. Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. J Med Chem 1999; 42: 3852-9.
10. Gao Y. Glycopeptide antibiotics and development of inhibitors to overcome vancomycin resistance, Nat Prod Rep 2002; 19: 100-7.
11. Kristiansen JE, Hendricks O, Devlin T, et al. Reversal of resistance in microorganisms by help of non-antibiotics. J Antimicrob Chemother 2007; 59: 1271-9.
12. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginoso: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-16.
13. Coban AY, Ekinci B, Durupinar B. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy 2004; 50: 22-6.
14. Mesaros N, Glupczynski Y, Avrain L, et al. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 2007; 59: 378-86.
15. Çoban AY, Birinci A, Ekinci B, et al. Investigation of the effects of efflux pump inhibitors on ciprofloxacin MIC values of high level fluoroquinolone resistant Escherichia coli clinical isolates. Mikrobiyol Bul 2004; 38: 21-5.
16. Kern WV, Steinke P, Schumacher A, et al. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 2006; 57: 339-43.
17. Bohnert AJ, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 2005; 49: 849-52.
18. Saenz Y, Ruiz J, Zarazaga M, et al. Effect of the pump inhibitor phe-arg-beta-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in Escherichia coli isolates of different origin. J Antimicrob Chemother 2004; 53: 544-5.
19. Pannek S, Higgins P, Steinke P, et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J Antimicrob Chemother 2006; 57: 970-4.
20. Gibbons S, Oluwatuyi M, Kaatz GW. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 13-7.
21. Schmitz FJ, Fluit AC, Lückefahr M, et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 807-10.
22. Vidaillac C, Guillon J, Arpin C, et al. Synthesis of omeprazole analogues and evaluation of these as potantial inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 831-8.
23. Aeschlimann JR, Dresser LD, Kaattz GW, et al. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 335-40.